{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:30:25Z","timestamp":1740133825481,"version":"3.37.3"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1120","license":[{"start":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T00:00:00Z","timestamp":1548374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Paget\u2019s disease of bone is characterised by overactive osteoclasts that resorb bone at a higher rate than normal. Osteoblasts attempt to repair the damage by laying down new bone which in turn is resorbed leaving a chaotic pattern of lytic and dense sclerotic bone behind. Deformed bone enlarges, becomes vascularised, bends and fractures. No bone is exempt but the skull, pelvis, vertebrae and long bones are commonly affected. Pressure from pagetic bone impinges on the auditory, facial, optic, trigeminal nerves and the spinal cord, risking paraplegia or quadriplegia. Vascular complications include cardiac failure and vertebrobasilar insufficiency. Serum alkaline phosphatase and urine N-telopeptide were used to assess response to treatment with porcine, salmon and human calcitonins, glucagon and bisphonates given alone or in combination. Glucagon has few side effects and controls the disease very rapidly. It can be given alone but because remissions last a few months, repeat courses may be necessary to achieve a long-term permanent quiescent bone state. If complete disease remission is not achieved with the hormone alone, an oral or intravenous bisphosphonate is given at the end of glucagon treatment. Other options are a second-generation bisphosphonate given orally to patients who decline parenteral medication. It remains to be seen whether glucagon affects other bone disorders.<\/jats:p>","DOI":"10.1136\/postgradmedj-2018-136193","type":"journal-article","created":{"date-parts":[[2019,1,26]],"date-time":"2019-01-26T00:01:20Z","timestamp":1548460880000},"page":"85-90","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Possible role for glucagon in the control of Paget\u2019s disease of bone"],"prefix":"10.1093","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5543-5242","authenticated-orcid":false,"given":"John Rhys","family":"Condon","sequence":"first","affiliation":[{"name":"Department of Medicine, Greenwich University Hospital , London SE19 3PS , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,1,25]]},"reference":[{"key":"2023041306473438400_","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/jcp.2009.064428","article-title":"Recent advances in understanding the molecular basis of Paget disease of bone","volume":"63","author":"Goode","year":"2010","journal-title":"J Clin Pathol"},{"key":"2023041306473438400_","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/095952877706000105","article-title":"On a form of chronic inflammation of bone","volume":"65","author":"Paget","year":"1877","journal-title":"J Med Chirug Trans"},{"key":"2023041306473438400_","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02546407","article-title":"Osteoclast ultrastructure in Paget\u2019s disease","volume":"20","author":"Rebel","year":"1976","journal-title":"Calcif Tissue Res"},{"key":"2023041306473438400_","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1177\/014107688407701110","article-title":"Viral aetiology of Paget\u2019s disease of bone: a review","volume":"77","author":"Harvey","year":"1984","journal-title":"J R Soc Med"},{"key":"2023041306473438400_","first-page":"104","article-title":"Atlas of Mineralised bone histology","volume":"106","author":"Malluch","year":"1986","journal-title":"Pub Karger"},{"key":"2023041306473438400_","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/art.1780231008","article-title":"Musculoskeletal manifestations of Paget\u2019s disease of bone","volume":"23","author":"Altman","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2023041306473438400_","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S8756-3282(02)00817-7","article-title":"Guidelines on the management of Paget\u2019s disease of bone","volume":"31","author":"Selby","year":"2002","journal-title":"Bone"},{"key":"2023041306473438400_","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/bmj.1.5746.421","article-title":"Treatment of Paget\u2019s disease of bone with mithramycin","volume":"1","author":"Condon","year":"1971","journal-title":"Br Med J"},{"key":"2023041306473438400_","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1210\/endo-70-5-638","article-title":"Evidence for calcitonin \u2013 a new hormone from the parathyroid that lowers blood calcium","volume":"70","author":"Copp","year":"1962","journal-title":"Endocrinology"},{"key":"2023041306473438400_","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1172\/JCI107140","article-title":"Calcitonin resistance: clinical and immunologic studies in subjects with Paget\u2019s disease of bone treated with porcine and salmon calcitonins","volume":"51","author":"Haddad","year":"1972","journal-title":"J Clin Invest"},{"key":"2023041306473438400_","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.52.8.616","article-title":"Treatment of Paget\u2019s disease of bone with single dose intravenous pamidronate","volume":"52","author":"Watts","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"2023041306473438400_","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","article-title":"Adverse effects of bisphosphonates: implications for osteoporosis management","volume":"84","author":"Kennel","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"2023041306473438400_","first-page":"1988","article-title":"Alendronate Once Weekly Study Group. Two year results of once Weekly administration of alendroate 70mg FoF the treatment of postmenopausal osteoporosis","volume":"2002","author":"Rizzoli","year":"1996","journal-title":"J Bone Miner. Res"},{"key":"2023041306473438400_","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/00003088-200544060-00001","article-title":"Pharmacokinetics\/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis","volume":"44","author":"Cremers","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2023041306473438400_","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1997.12.10.1700","article-title":"Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis","volume":"12","author":"Khan","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2023041306473438400_","first-page":"167","article-title":"The role of glucagon hypersecretion in the relationship of pancreatitis and hyperparathyrotism","author":"Paloyan","year":"1967"},{"key":"2023041306473438400_","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1210\/jcem-29-2-213","article-title":"Glucagon hypercalcaemia in man","volume":"29","author":"Birge","year":"1969","journal-title":"J Clin Endocrinol"},{"key":"2023041306473438400_","first-page":"209","article-title":"Osteoclast ontology and function","author":"Mundy","year":"1987","journal-title":"Ed. Peck W P, in Bone and Mineral Research V"},{"key":"2023041306473438400_","first-page":"651","article-title":"Glucagon and blood sugar","volume":"295","author":"Condon","year":"1976","journal-title":"N Engl J Med"},{"key":"2023041306473438400_","first-page":"653","article-title":"Glucagon and blood sugar","volume":"295","author":"Felig","year":"1976","journal-title":"N Engl J Med"},{"key":"2023041306473438400_","doi-asserted-by":"crossref","first-page":"278","DOI":"10.5694\/j.1326-5377.1981.tb128316.x","article-title":"Paget\u2019s disease of bone: experiences with 100 patients treated with salmon calcitonin","volume":"2","author":"Grunstein","year":"1981","journal-title":"Med J Aust"},{"key":"2023041306473438400_","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1136\/bmj.4.5789.719","article-title":"Glucagon in the treatment of Paget\u2019s disease of bone","volume":"4","author":"Condon","year":"1971","journal-title":"Br Med J"},{"key":"2023041306473438400_","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/pgmj.57.664.84","article-title":"Control of osteitis deformans using glucagon, calcitonin, and mithramycin","volume":"57","author":"Condon","year":"1981","journal-title":"Postgrad Med J"},{"key":"2023041306473438400_","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.mehy.2016.09.014","article-title":"Inhibition of cancer cell mitosis by reducing the availability of phosphate","volume":"96","author":"Condon","year":"2016","journal-title":"Med Hypotheses"},{"key":"2023041306473438400_","article-title":"Glucagon. Molecular physiology clinical and therapeutic implications","author":"Lefebvre","year":"1972","journal-title":"Permagon Press"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/95\/1120\/85\/49809686\/postgradmedj-95-85.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/95\/1120\/85\/49809686\/postgradmedj-95-85.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T06:07:49Z","timestamp":1694585269000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/95\/1120\/85\/6983933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,25]]},"references-count":25,"journal-issue":{"issue":"1120","published-online":{"date-parts":[[2019,1,25]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1136\/postgradmedj-2018-136193","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"type":"print","value":"0032-5473"},{"type":"electronic","value":"1469-0756"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2019,1,25]]}}}